Celularity Inc. Class A Common Stock
CELU
CELU: Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases.
moreShow CELU Financials
Recent trades of CELU by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CELU's directors and management
Government lobbying spending instances
-
$10,000 Jul 18, 2023 Issue: Health Issues
-
$10,000 Apr 19, 2023 Issue: Health Issues
-
$10,000 Jan 17, 2023 Issue: Health Issues
-
$10,000 Oct 19, 2022 Issue: Health Issues
-
$10,000 Jul 19, 2022 Issue: Health Issues
-
$10,000 Apr 19, 2022 Issue: Health Issues
-
$10,000 Jan 19, 2022 Issue: Health Issues
-
$10,000 Oct 19, 2021 Issue: Health Issues
-
$10,000 Jul 19, 2021 Issue: Health Issues
New patents grants
Federal grants, loans, and purchases
Followers on CELU's company Twitter account
Number of mentions of CELU in WallStreetBets Daily Discussion
Recent insights relating to CELU
Recent picks made for CELU stock on CNBC
ETFs with the largest estimated holdings in CELU
Flights by private jets registered to CELU